Metabolic syndrome in bipolar disorder and schizophrenia: dietary and lifestyle factors compared to the general population by Bly, Michael J et al.
Original Article
Metabolic syndrome in bipolar disorder and
schizophrenia: dietary and lifestyle factors
compared to the general population
Bly MJ, Taylor SF, Dalack G, Pop-Busui R, Burghardt KJ, Evans SJ,
McInnis MI, Grove TB, Brook RD, Z€ollner SK, Ellingrod VL.
Metabolic syndrome in bipolar disorder and schizophrenia: dietary and
lifestyle factors compared to the general population.
Bipolar Disord 2014: 16: 277–288. © 2013 John Wiley & Sons A/S.
Published by John Wiley & Sons Ltd.
Objective: Since a poor diet is often cited as a contributor to metabolic
syndrome for subjects diagnosed with bipolar disorder and
schizophrenia, we sought to examine dietary intake, cigarette smoking,
and physical activity in these populations and compare them with those
for the general population.
Methods: Individuals diagnosed with bipolar disorder (n = 116) and
schizophrenia (n = 143) were assessed for dietary intake, lifestyle habits,
and metabolic syndrome and compared to age-, gender-, and race-
matched subjects from the National Health and Nutrition Examination
Survey (NHANES) 1999–2000. Additionally, matched subgroups within
the patient populations were compared to elicit any diﬀerences.
Results: As expected, the metabolic syndrome rate was higher in the
samples with bipolar disorder (33%) and schizophrenia (47%) compared
to matched NHANES controls (17% and 11%, respectively), and not
diﬀerent between the patient groups. Surprisingly, both subjects with
bipolar disorder and those with schizophrenia consumed fewer total
calories, carbohydrates and fats, as well as more ﬁber (p < 0.03),
compared to NHANES controls. No dietary or activity diﬀerences
between patient participants with and without metabolic syndrome were
found. Subjects with schizophrenia had signiﬁcantly lower total and low-
density cholesterol levels (p < 0.0001) compared to NHANES controls.
Subjects with bipolar disorder smoked less (p = 0.001), exercised more
(p = 0.004), and had lower body mass indexes (p = 0.009) compared to
subjects with schizophrenia.
Conclusions: Counter to predictions, few dietary diﬀerences could be
discerned between schizophrenia, bipolar disorder, and NHANES
control groups. The subjects with bipolar disorder exhibited healthier
behaviors than the patients with schizophrenia. Additional research
regarding metabolic syndrome mechanisms, focusing on non-dietary
contributions, is needed.
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The relationships between cardiovascular disease
and medication use for those diagnosed with
bipolar disorder and schizophrenia are gaining
increasing attention. In looking at our previous
work as well as other reports in the literature, we
found that approximately 40% of those with a
serious mental illness met National Cholesterol
Education Panel-Adult Treatment Panel III
(NCEP-ATP-III) guidelines for metabolic syn-
drome (1–6). Many groups have suggested a
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pharmacogenetic risk for metabolic syndrome (5–
7). However, a poor diet and unhealthy lifestyle
choice, such as cigarette smoking and lack of
physical activity, are major cardiovascular disease
contributors and often seen in patients with a
serious mental illness (8–11). While the literature
examining relationships between diet, lifestyle,
and cardiovascular disease within the general
population is broad, little has been done among
those with serious mental illness. For these indi-
viduals, up to 30 years of life are lost due to car-
diovascular disease (12). This may be due to the
higher rate of metabolic syndrome (~40%) within
this group (1). Thus, in addition to understanding
the medication and genetic risks associated with
cardiovascular disease in mental health disorders,
understanding overall dietary and lifestyle charac-
teristics within populations with a serious mental
illness is critical to prevent premature death and
develop individualized interventions to prevent
metabolic syndrome. In order to do this, a thor-
ough understanding of the dietary and lifestyle
habits for each of these groups is needed (13).
Thus, the primary aim of this study was to
examine dietary intake in community-dwelling
subjects diagnosed with bipolar disorder and
schizophrenia compared to that for the general
population using age-, race-, and gender-matched
subjects from the National Health and Nutrition
Examination Survey (NHANES) 1999–2000 data.
For this investigation, we also decided to speciﬁ-
cally focus on the intake of the essential fatty acids
(EFAs), since our group reported that atypical an-
tipsychotics may neutralize the cardiovascular ben-
eﬁts of omega 3 fatty acid intake (14); however,
EFA intake in schizophrenia is particularly under-
studied, as is the general study of dietary intake
within this population. Our secondary aim was to
examine diﬀerences between age-, race-, and gen-
der-matched subjects with bipolar disorder and
schizophrenia in regard to dietary intake (both
general dietary intake and dietary intake related to
EFAs), as well as lifestyle behaviors (smoking and
exercise) and their relationship to metabolic syn-
drome. Our hypothesis was that NHANES sub-
jects, matched on age, race, and gender, would
display healthier dietary choices compared to those
with a serious mental illness. We also hypothesized
that the matched bipolar disorder and schizophre-
nia groups would have few diﬀerences in dietary
intake and lifestyle behaviors. Lastly, we hypothe-
sized that subjects meeting metabolic syndrome
criteria would have poorer overall and EFA-spe-
ciﬁc dietary intake, increased rates of smoking and
low physical activity compared to those without
metabolic syndrome.
Methods
Study subjects with bipolar disorder and schizophrenia
Subjects in this analysis met the following inclusion
criteria: (i) DSM-IV diagnosis of schizophrenia,
schizophreniform disorder, schizoaﬀective disor-
der, or bipolar disorder type I or type II; (ii)
≥18 years of age; and (iii) pharmacologic mental
health treatment for at least six months. Subjects
were excluded if they: (i) were unable to provide
informed consent (assessed using a short question-
naire asking key questions about the study); (ii)
had documented type II diabetes before antipsy-
chotic treatment started; or (iii) had a documented
active substance abuse diagnosis. The inclusion
and exclusion criteria for this study were broad in
an eﬀort to represent ‘real world’ practice. These
criteria did not include any additional medical-
related inclusion or exclusion criteria. Study sub-
jects were recruited from ambulatory care mental
health clinics and were included in a previous phar-
macogenomics study related to the occurrence of
atypical antipsychotic-associated metabolic com-
plications (5) as well as in the Prechter Longitudi-
nal Study of Bipolar Disorder (15). The study
protocols were approved by the University of
Michigan Medical School Institutional Review
Board (IRBMED) and informed consent was
obtained from all subjects.
National Health and Nutrition Examination Survey
(NHANES) subject data
Age- (within three years), race-, and gender-
matched controls from the general population for
each subject were obtained through the National
Health and Nutrition Examination Survey
(NHANES) 1999–2000 database (16). From this
database, we extracted data related to dietary
intake, laboratory values, and demographics in
order to compare the NHANES subjects with the
matched subjects with bipolar disorder and schizo-
phrenia. We were unable to match the subjects
with bipolar disorder and schizophrenia with the
NHANES controls in regard to education, years of
employment, living situation, or socioeconomic
status.
Assessments
Subjects with bipolar disorder and schizophrenia
meeting inclusion and exclusion criteria underwent
a procedure to obtain informed consent, including
a brief assessment of the risks and beneﬁts associ-
ated with study participation. After consent had
been obtained, a clinical interview, which included
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the Structured Clinical Interview for DSM diagno-
ses (SCID) for patients with schizophrenia (17) or
the Diagnostic Interview for Genetic Studies
(DIGS) for the subjects with bipolar disorder (18),
was completed by a trained research assistant to
conﬁrm the psychiatric diagnosis. Diﬀerent diag-
nostic instruments were used since the patients
came from two diﬀerent primary studies, although
the procedures used for gathering all other data
were identical across subject groups. Subjects
underwent a thorough assessment of current and
past medication history which was conﬁrmed by
medical record review. This information was used
to calculate overall antipsychotic exposure using
chlorpromazine equivalents (19). Our primary
atypical antipsychotic (AAP) group included those
receiving olanzapine, clozapine, quetiapine, risperi-
done, and paliperidone, similar to our previous
investigations (5, 6, 14). Ziprasidone and aripipraz-
ole were not included in the primary classiﬁcation
due to their reduced potential to cause weight gain
and metabolic syndrome; however, our secondary
analysis did include these two medications as atyp-
ical antipsychotics (20).
Subjects fasted (for >8 hours) before the study
visits, which took place between 8 a.m and noon,
or within two hours of their usual waking time
based on appointment availability. Vital signs (i.e.,
height and weight) and hip and waist circumfer-
ences were measured for each subject and body
mass index (BMI) was calculated.
Subjects diagnosed with bipolar disorder or
schizophrenia recalled all foods eaten for the previ-
ous 24 hours prior to fasting, and this was
repeated twice within the next 10 days for a total
of three assessments. The methods used to conduct
this assessment were identical to the 24-hour food
recount conducted as part of the NHANES study
(see http://www.cdc.gov/nchs/tutorials/dietary/sur
veyorientation/dietarydataoverview/info2.htm for
additional information regarding this assessment).
For both our study and the NHANES study, a
standardized script was used during an in-person
interview. This was then repeated by telephone
once more for the NHANES study and twice more
for our studies within 10 days after the initial inter-
view. Our assessments were administered by the
registered dieticians from the Michigan Clinical
Research Unit (MCRU) using a standardized pro-
tocol outlined on the NHANES tutorial and
included using standard measuring guides as tools
to help subjects accurately report the volume and
dimensions of foods consumed in the previous
24 hours. This standardized assessment has been
used extensively within the dietary literature and
provides high-quality intake data with minimal
bias (21–23). The 24-hour recall has become the
preferred tool for monitoring diets of various pop-
ulations for the study of disease and diet associa-
tions (24) and has been previously used in diﬀerent
schizophrenia populations (25). Data obtained
from these recalls from both our studies as well as
the NHANES dataset were then used to calculate
average calorie intake using the Nutrition Data
Systems for Research (NDSR) software developed
by the Nutrition Coordinating Center (NCC) at
the University of Minnesota (26). The output from
these analyses was averaged over the two recalls
for the NHANES controls and three recalls for the
subjects with bipolar disorder and schizophrenia.
This output provides values for more than 140
nutrients, nutrient ratios, and other compounds
based on the information gathered. Based on our
previous ﬁnding that atypical antipsychotics may
blunt the cardio-protective eﬀects of omega 3 fatty
acids (14), we chose to focus on dietary intake
related to essential fatty acids [omega 3 fatty acids
(N-3) and omega 6 fatty acids (N-6)], the N-3/N-6
ratio, total fat, and saturated fatty acids (SFAs),
and polyunsaturated fat acids (PUFAs). We also
included more general measurements of caloric
intake such as total calories, carbohydrates, dietary
ﬁber, and glycemic index in an eﬀort to understand
overall dietary intake.
The smoking and physical activity assessments
for the subjects with bipolar disorder and schizo-
phrenia consisted of questions about smoking
(number of cigarettes smoked per day, age when
smoking stated, and quit date if applicable) to
calculate a smoking pack-year history. An assess-
ment of average physical activity was also
obtained using the Total Activity Measure 2
(TAM2) which measures total or moderate-inten-
sity physical activity for participants and has been
validated against RT3 triaxial accelerometer mea-
surements in a population with coronary heart
disease (27). A higher score indicates greater
physical activity over the past week and the score
is reported in metabolic equivalent (MET)/min.
Data related to these lifestyle assessments were
not available for the NHANES controls.
Blood was obtained from fasting subjects with
bipolar disorder and schizophrenia for the follow-
ing assessments: glucose, insulin, hemoglobin
A1c, and lipids [total cholesterol (TC), high-
density lipoprotein (HDL), and low-density lipo-
protein (LDL)]. Subjects were determined to have
a diagnosis of metabolic syndrome using the
NCEP-ATP III guidelines (3), based on the
results of the laboratory and clinical measure-
ments. Metabolic syndrome is deﬁned as having
any three of the following: (i) abdominal obesity
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characterized by waist circumference of
>40 inches for men and >35 inches for women;
(ii) triglycerides ≥150 mg/dL; (iii) HDL choles-
terol <40 mg/dL for men and <50 mg/dL for
women or receiving a lipid-lowering agent; (iv)
blood pressure ≥130/≥85 mmHg or treatment for
hypertension; or (v) fasting glucose ≥100 mg/dL
or treatment of diabetes. Insulin resistance was
calculated using the homeostasis model assess-
ment–insulin resistance (HOMA-IR). Data on
these laboratory values for control subjects were
obtained through NHANES (16).
Statistical analysis
All analyses were conducted using JMP version 8
or 9 (SAS Institute, Cary, NC, USA). For our
primary aim, we examined diﬀerences between the
subjects with bipolar disorder or schizophrenia
compared to NHANES matched subjects on race,
gender, and age (within three years). For our sec-
ond analysis, we were interested in determining
diﬀerences between the subjects with bipolar dis-
order and schizophrenia, and thus subjects within
these two groups were also matched by race, gen-
der, and age (within three years), resulting in a
smaller subset of these patients being included in
this analysis.
Diﬀerences for the primary outcomes and soci-
odemographic variables between diagnostic and
metabolic syndrome groups were determined by
the use of one-way analysis of variance (ANOVA)
for normally distributed variables (BMI, waist
circumference, age, metabolic measures, dietary
intake, and the physical activity assessment). Chi-
squared analyses compared dichotomous vari-
ables (e.g., gender, smoking status, and atypical
antipsychotic use) by diagnostic and metabolic
syndrome groups. Our dietary analysis using the
NDSR database resulted in a plethora of infor-
mation. As stated above, we decided a priori to
focus on dietary intake measures of approxi-
mately 10 diﬀerent values for our initial analysis,
since our previous work has shown a relationship
between omega 3 fatty acid intake, atypical anti-
psychotic use, and endothelial functioning (14).
These values are listed in Tables 1 and 2 and
discussed below. A general linear regression was
performed to determine dietary and lifestyle pre-
dictors of metabolic syndrome using metabolic
syndrome (and its individual components) as the
dependent variables, and age, race, gender, AAP
use, and dietary and lifestyle measurements as
independent variables. A p-value less than 0.05
was considered statistically signiﬁcant due to the
exploratory nature of this investigation.
Results
Characteristics of subjects diagnosed with bipolar
disorder or schizophrenia, and NHANES controls
A total of 143 subjects with schizophrenia, 116
subjects with bipolar disorder, and 259 age- (within
three years), gender-, and race-matched subjects
from NHANES (1999–2000) were included (16).
Table 1 outlines group characteristics. In general,
47% of our schizophrenia group and 33% of our
bipolar disorder group met criteria for metabolic
syndrome; the diﬀerence was not statistically dif-
ferent (p = 0.52). These rates are signiﬁcantly
higher than those seen in the NHANES controls
(11% and 17% for those matched to subjects in
the schizophrenia and bipolar disorder groups,
respectively) as well as the 20–25% rate reported in
the literature (Table 1). Both the bipolar disorder
and schizophrenia groups had diﬀerences in most
metabolic measures (i.e., higher BMI, blood pres-
sure, and glucose) compared to the NHANES sub-
jects. Interestingly, the schizophrenia group had
signiﬁcantly lower lipid measurements compared
to the NHANES subjects (total cholesterol
169 mg/dL versus 196 mg/dL, respectively, p <
0.0001), while no diﬀerences were found for the
bipolar disorder group compared to the NHANES
subjects (191 mg/dL versus 188 mg/dL, respec-
tively, p = 0.51).
Dietary diﬀerences between the mental illness
groups and the NHANES subjects are detailed in
Table 2. In general, both the bipolar disorder and
schizophrenia groups reported consuming signiﬁ-
cantly less calories (p = 0.031) and less carbohy-
drates (p < 0.0001) than NHANES subjects. The
bipolar disorder group also reported a signiﬁcantly
lower intake of saturated fatty acids (p = 0.007),
fat in general (p = 0.048) and monounsaturated
fatty acids (p = 0.03). No other diﬀerences were
found in the average dietary intake for either the
bipolar disorder or schizophrenia group compared
to the NHANES subjects. However, the omega 6
to omega 3 (N-6/N-3) ratio for the NHANES sub-
jects was signiﬁcantly higher than that for the sub-
jects with schizophrenia (p = 0.02), although for
the schizophrenia and bipolar disorder groups and
their matched NHANES groups, this ratio was
around 10, which is above the recommended
intake ratio of one to four (28).
Differences between matched subjects with bipolar
disorder and schizophrenia
In order to determine disease-speciﬁc diﬀerences in
diet and lifestyle factors that may aﬀect metabolic
syndrome occurrence, a subset of our subjects with
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bipolar disorder and schizophrenia were also
matched by race, gender, and age (within three
years), resulting in 78 matches for a ﬁnal sample
size of 156. A total of 103 subjects (65 from the
schizophrenia group and 38 from the bipolar disor-
der group) did not have a match and were excluded
from this analysis. The mean  standard deviation
age of this group was 45.1  10.9 years, and 60%
were female, 80% were Caucasian, and 13% were
African American. A description of demographic,
Table 1. Differences in laboratory and dietary measures between
age-, race-, and gender-matched patients with schizophrenia and
bipolar disorder, and general population controls
Measurement
Schizophrenia
(n = 143)
NHANES
matches
(n = 143) p-value
Age, years 45.8 (11.2) 45.9 (11.2) 1
Race, Caucasian/
African
American, %
61/30 61/30 1
Gender,
male/female, %
64/36 64/36 1
Meeting
metabolic
syndrome, %
47 11 <0.0001
BMI, kg/m2 33.0 (8.2) 26.6 (6.6) <0.0001
Systolic BP,
mm Hg
124.6 (17.1) 122.3 (21.3) 0.0052
Diastolic BP,
mm Hg
75.9 (12.7) 70.8 (14.3) 0.0012
Homocysteine,
lmol/L
11.4 (5.0) 6.5 (2.5) <0.0001
Total
cholesterol, mg/dL
169.0 (42.7) 196.4 (44.4) <0.0001
HDL, mg/dL 50.1 (15.7) 50.5 (13.6) 0.85
LDL, mg/dL 101.0 (31.7) 127.4 (48.7) <0.0001
Triglycerides, mg/dL 137.5 (101.5) 127.7 (76.3) 0.61
Blood glucose,
mg/dL
107.3 (53.3) 88.6 (18.4) <0.0001
HOMA-IR 6.6 (6.2) 3.3 (2.8) <0.0001
Measurement Bipolar
disorder
(n = 116)
NHANES
matches
(n = 116)
Age, years 43.3 (12.1) 42.5 (12.2) 1
Race, Caucasian/
African American, %
82/11 82/11 1
Gender,
male/female, %
34/66 34/66 1
Meeting metabolic
syndrome, %
33 17 <0.0001
BMI, kg/m2 32.3 (8.7) 25.4 (5.9) <0.0001
Systolic BP,
mm Hg
123.6 (18.1) 116.6 (16.7) 0.58
Diastolic BP,
mm Hg
73.0 (10.9) 69.9 (13.0) 0.07
Homocysteine,
lmol/L
10.5 (3.3) 6.6 (2.7) <0.0001
Total cholesterol,
mg/dL
191.5 (44.9) 187.7 (40.9) 0.51
HDL, mg/dL 57.4 (15.1) 50.5 (13.4) 0.0005
LDL, mg/dL 118.2 (38.4) 111.3 (30.1) 0.23
Triglycerides,
mg/dL
146.4 (106.3) 155.2 (158.8) 0.62
Blood glucose,
mg/dL
101.9 (31.1) 91.0 (14.0) 0.018
HOMA-IR 8.2 (13.1) 3.4 (3.1) <0.0001
Values are presented as mean (standard deviation) unless
noted otherwise. BMI = body mass index; BP = blood pressure;
HDL = high-density lipoprotein; HOMA-IR = Homeostasis
Model of Assessment–Insulin Resistance; LDL = low-density
lipoprotein; NHANES = National Health and Nutrition Examina-
tion Survey.
Table 2. Comparison of dietary and lifestyle variables between
groups: comparison of dietary intake and lifestyle measures between
age-, race-, and gender-matched patients with schizophrenia and
bipolar disorder, and National Health and Nutrition Examination Survey
(NHANES) matches
Measurement
(consumed)
Schizophrenia
(n = 143)
NHANES
matches
(n = 143) p-value
Energy,
kcal/day
2,072 (736) 2,291 (1,084) 0.031
Carbohydrates,
g/day
260.9 (100.6) 294.0 (151.7) 0.037
Saturated fatty
acids, g/day
28.3 (11.8) 28.5 (17.8) 0.89
Fiber, g/day 17.2 (9.0) 12.2 (8.8) <0.0001
Fat, g/day 81.4 (33.1) 85.4 (49.0) 0.39
Polyunsaturated
fatty acids, g/day
17.1 (9.4) 17.8 (11.6) 0.57
Protein, g/day 79.0 (32.9) 82.0 (43.4) 0.47
Monounsaturated
fatty acids, g/day
29.3 (12.7) 32.6 (19.6) 0.08
Omega 3 fatty
acids, g/day
1.7 (0.9) 1.7 (1.3) 0.94
Omega 6 fatty
acids, g/day
16.9 (9.3) 16.8 (11.8) 0.98
Omega 6/
omega 3 ratio
10.8 (3.8) 13.0 (13.7) 0.02
Measurement
(consumed)
Bipolar
disorder
(n = 116)
NHANES
matches
(n = 116)
Energy, kcal/day 1,896 (609) 2,309 (1,021) 0.0005
Carbohydrates,
g/day
241.0 (92.2) 300.5 (172.6) 0.0007
Saturated fatty
acids, g/day
24.4 (11.9) 29.6 (16.2) 0.0073
Fiber, g/day 19.0 (10.2) 14.7 (9.7) 0.0007
Fat, g/day 74.3 (31.2) 84.7 (41.3) 0.048
Polyunsaturated
fatty acids, g/day
16.6 (7.5) 16.7 (9.9) 0.96
Protein, g/day 73.3 (22.9) 82.3 (38.8) 0.056
Monounsaturated
fatty acids, g/day
27.3 (12.8) 31.8 (16.6) 0.030
Omega 3 fatty
acids, g/day
1.8 (0.9) 1.6 (1.1) 0.16
Omega 6 fatty
acids, g/day
16.3 (7.5) 16.5 (10.0) 0.86
Omega 6/
omega 3 ratio
9.9 (4.2) 10.8 (3.1) 0.38
Values are presented as mean (standard deviation).
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dietary, lifestyle, and metabolic diﬀerences between
the patients with bipolar disorder and schizophre-
nia is given in Table 3.
Similar to the previous analysis, we examined
diﬀerences in both metabolic measures and dietary
intake. There was a signiﬁcant diﬀerence between
the two groups related to cholesterol, as the bipo-
lar disorder group had higher total cholesterol
measurements (194 mg/dL versus 174 mg/dL,
respectively, p = 0.009) and LDL cholesterol mea-
surements (120.3 mg/dL versus 102.7 mg/dL,
respectively, p = 0.005) compared to subjects with
schizophrenia. We had hypothesized that this
might be due to a diﬀerence in lipid-lowering medi-
cations between these groups, but as can be seen
from Table 3, this was not the case, as use of these
medications in general was low overall (25%). For
other metabolic indices, there were no statistically
signiﬁcant diﬀerences in fasting glucose (p = 0.67),
insulin resistance (HOMA-IR, p = 0.35) blood
pressure (p = 0.63), or BMI (p = 0.13) between the
two groups, and both groups met criteria for obes-
ity (BMI > 30 mm/kg2). In terms of central adi-
posity, the schizophrenia group had a much lower
hip/waist ratio compared to those with bipolar dis-
order (p = 0.02), suggesting greater central adipos-
ity for those with schizophrenia (11). Additionally,
the rate of AAP use among the bipolar disorder
Table 3. Description of demographic, dietary intake, and metabolic differences between age-, race-, and gender-matched patients with schizophre-
nia and bipolar disorder
Variable Schizophrenia (n = 78) Bipolar disorder (n = 78) p-value
Demographics
Age, years, mean (SD) 45.1 (10.9) 46.1 (10.9) 0.59
Race, Caucasian/African American, % 77/17 84/12 0.29
Gender, male, % 40 40 1
Atypical antipsychotic use, % 74 53 0.009
Metabolic parameters
BMI, kg/m2, mean (SD) 34.1 (8.7) 32.1 (7.7) 0.13
Hip/waist ratio, mean (SD) 1.05 (0.09) 1.09 (0.11) 0.02
Systolic BP, mmHg, mean (SD) 122 (18) 124 (19) 0.63
Diastolic BP, mmHg, mean (SD) 74 (12) 74 (11) 0.98
Homocysteine, lmol/L, mean (SD) 11.3 (6.0) 10.8 (3.4) 0.64
Total cholesterol, mg/dL, mean (SD) 173.9 (46.2) 194.5 (49.3) 0.009
HDL, mg/dL, mean (SD) 54.5 (17.5) 56.7 (16.0) 0.43
LDL, mg/dL, mean (SD) 102.7 (33.4) 120.3 (41.8) 0.005
Triglycerides, mg/dL, mean (SD) 134.9 (101.7) 160.2 (111.3) 0.15
Glucose, mg/dL, mean (SD) 107.2 (46.6) 104.4 (36.7) 0.67
Meeting ATP-III metabolic syndrome criteria, % 42 37 0.52
HOMA-IR, mean (SD) 6.7 (6.9) 8.7 (16.1) 0.35
Dietary and lifestyle parameters
Current smoker, % 70 45 0.001
Total activity score (TAM2), MET/min, mean (SD) 2,423 (2,492) 4,027 (4,096) 0.004
Total calories, kcal/day, mean (SD)a 1,990 (735) 1,953 (656) 0.74
Carbohydrates, kcal/day, mean (SD)a 250 (100) 246 (96) 0.82
Total fat, g/day, mean (SD)a 79 (35) 77 (34) 0.71
PUFA, g/day, mean (SD)a 17 (10) 17 (8) 0.96
SFA, g/day, mean (SD)a 29 (12) 26 (13) 0.30
Dietary fiber, g/day, mean (SD)a 18 (10) 18 (9) 0.71
Glycemic index (glucose reference), mean (SD) 59.4 (4.9) 60.2 (7.4) 0.39
Omega 3 fatty acids, g/day, mean (SD)a 1.9 (0.9) 1.8 (1.0) 0.16
Omega 6 fatty acids, g/day, mean (SD)a 16.6 (9.7) 16.6 (7.9) 0.98
Omega 6/omega 3 ratio, mean (SD) 11.1 (4.3) 10.1 (4.7) 0.17
Medications
Cumulative chlorpromazine equivalents, mg, mean (SD) 439.7 (326.8) 247.4 (308.2) 0.0002
Mood stabilizer, %b 30 79 <0.0001
Antidepressant, %b 54 60 0.42
Anti-hypertensive, %b 31 28 0.73
Lipid lowering medication, %b 29 22 0.27
Oral hypoglycemic medication, %b 15 6 0.22
BMI = body mass index; BP = blood pressure; HDL = high-density lipoprotein; HOMA-IR = Homeostasis Model of Assessment–Insulin
Resistance; LDL = low-density lipoprotein; PUFA = polyunsaturated fatty acids; SD = standard deviation; SFA = saturated fatty acids.
aAmount consumed per day.
bCurrent medication.
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and schizophrenia groups was diﬀerent. Seventy-
four percent of those with schizophrenia and 53%
of those with bipolar disorder were receiving an
AAP at the time of assessment, and those with
schizophrenia had a higher overall chlorpromazine
equivalent measurement (p = 0.0002), which is in
line with the ﬁrst-line treatments for each of these
serious mental illnesses. As previously stated, as
part of our primary analysis we did not include
subjects taking the medications aripiprazole or zip-
rasdone within the AAP group due to a lower
reported propensity for weight gain and other met-
abolic consequences (29). When these medications
were included in our secondary analysis of AAP
classiﬁcation, 80% of the subjects with bipolar dis-
order and 84% of the subjects with schizophrenia
were receiving AAPs, a diﬀerence that was not sta-
tistically signiﬁcant (p = 0.22). We also compared
the use of other psychotropic medications between
the two groups and found more mood stabilizer
usage within the bipolar disorder group (79% ver-
sus 30%, respectively, p < 0.0001); however, no
diﬀerences were seen in regard to antidepressant,
antihypertensive, oral hypoglycemic, and lipid-
lowering agent usage (p > 0.20 for all).
In addition to the laboratory diﬀerences between
the two groups, no diﬀerences in dietary intake
were noted between the matched bipolar and
schizophrenia groups, as outlined in Table 3.
Given the previous relationship we reported
between AAP use and omega 3 fatty acid dietary
consumption, we wanted to examine essential fatty
acid intake among these groups. Most notably,
mean omega 3 fatty acid (N-3) intake was 1.8 g/
day, which is within the recommended consump-
tion of 1–2 g/day (30); however, the ratio of omega
6 to omega 3 fatty acids (N-6/N-3) was approxi-
mately 10 for each group, and current recommen-
dations are to maintain a ratio of around 1 to 4 for
optimal cardiovascular health (31). In terms of
other lifestyle diﬀerences, the bipolar disorder pop-
ulation displayed healthier choices than the schizo-
phrenia group in that fewer of them smoked
cigarettes (45% versus 70%, respectively,
p = 0.001) and they reported more physical activ-
ity (p = 0.004). Thus, despite reporting overall
healthier lifestyle choices, and having healthier
diets and lower AAP use compared to the subjects
with schizophrenia, those with bipolar disorder
still were at an increased risk for metabolic
syndrome.
Metabolic syndrome differences
For this analysis, the above mentioned age-, race-,
and gender-matched subjects with bipolar disorder
and schizophrenia were stratiﬁed by metabolic syn-
drome criteria (32). Group diﬀerences are outlined
in Table 4. Those with metabolic syndrome were
slightly older than those without metabolic syn-
drome (mean age 48 versus 43 years old, respec-
tively, p = 0.004), with no diﬀerences in race,
gender, or the percentage who smoked cigarettes.
Additionally, within both groups, approximately
60% reported AAP use (68% versus 57%, respec-
tively, p = 0.17); however, antidepressant use was
higher in the metabolic syndrome group (69% ver-
sus 49%, respectively, p = 0.01). When the pre-
determined dietary variables of interest were exam-
ined, no diﬀerences were found. Thus, despite
meeting criteria for metabolic syndrome, the diet
and lifestyle choices of those classiﬁed as having
metabolic syndrome appeared to be very similar to
those of subjects not meeting metabolic syndrome
criteria.
For our regression model, we examined the rela-
tionship between metabolic syndrome and the die-
tary and lifestyle parameters outlined in Table 4.
None of the dietary and lifestyle parameters were
speciﬁcally associated with metabolic syndrome,
except antidepressant use (v2 = 9.46, p = 0.002),
which remained signiﬁcant after controlling for age
(v2 = 5.54, p = 0.02). In fact, the odds ratio for
metabolic syndrome in antidepressant users was
2.24 (95% conﬁdence interval: 1.33–14.9).
Discussion
Overall, our study found metabolic diﬀerences
between patients with bipolar disorder or schizo-
phrenia and NHANES controls, which was not
surprising given extensive previous work (1, 33–
36). Contrary to expectations, the subjects with
bipolar disorder and schizophrenia showed similar
or better dietary intake than the NHANES sub-
jects, and for those with a serious mental illness,
dietary, smoking, and physical activity measure-
ments did not distinguish those with and without
metabolic syndrome, except for the use of antide-
pressants. Subjects with schizophrenia showed
lower total and LDL cholesterol levels, compared
to NHANES subjects, which is somewhat contra-
dictory to the existing hypotheses around AAP
use, lipid biosynthesis, and lipid utilization within
the schizophrenia population (37). While these
ﬁndings appear to contradict the received wisdom
about metabolic syndrome, we believe that they
actually provide an important insight into a major
health risk factor that might not be as straightfor-
ward as it seems.
It is widely assumed that metabolic syndrome is
largely associated with poor dietary habits, and
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while the literature shows ample support for this
thesis in the population at large (38), this has been
remarkably under-investigated in those with seri-
ous mental illness. Our bipolar and schizophrenia
groups exhibited few dietary diﬀerences compared
to the NHANES subjects. In fact, both of our
patient groups consumed fewer calories and more
ﬁber and few carbohydrates compared to controls.
Thus, these data directly contradict the theory that
a poor diet is primarily responsible for the
increased metabolic syndrome risk seen in those
with mental illness (39). Additionally, both the
subjects with bipolar disorder and those with
schizophrenia had a more favorable essential fatty
acid N-6/N-3 ratio compared to NHANES sub-
jects (Table 2). Elevations in this ratio are a poten-
tial cardiovascular disease risk factor (31, 40).
While group diﬀerences were statistically signiﬁ-
cant between the NHANES subjects and subjects
with schizophrenia, there was no statistically sig-
niﬁcant diﬀerence between NHANES subjects and
subjects with bipolar disorder. Clinically, though,
the impact of these diﬀerences is really unknown.
Although both the subjects with bipolar disorder
and those with schizophrenia are undoubtedly at
greater metabolic syndrome risk due to the pres-
ence of mental illness, as well as other pharmaco-
logic and non-pharmacologic risk factors,
compared to NHANES controls, our study sug-
gests that simply attributing this risk to diet does
not appear to be suﬃcient.
In an eﬀort to determine potential disease-spe-
ciﬁc diﬀerences that may be seen in dietary intake,
we also examined diﬀerences between our matched
subjects with bipolar disorder and schizophrenia,
since recent literature has suggested similar meta-
bolic syndrome risks (41, 42). Overall, the schizo-
phrenia group had more cigarettes smokers, and
they exercised less than the subjects with bipolar
disorder (Table 3), yet the rate of metabolic syn-
drome was similar. Additionally, subjects with
schizophrenia had lower total and LDL cholesterol
levels compared to the bipolar disorder group. No
diet intake diﬀerences were found between the two
groups, which was not expected. For medications,
the bipolar disorder group had higher mood stabi-
lizer use, with no particular one being most com-
mon. Valproic acid has been associated with
weight gain, but since only 25% of subjects with
bipolar disorder were receiving valproate, its use
cannot be signiﬁcantly contributing to the meta-
bolic diﬀerences we found. Similar rates of meta-
bolic syndrome were seen for both of the age-,
race-, and gender-matched groups, despite the fact
that the bipolar disorder group, in general, partici-
pated in healthier lifestyle choices (exercise and
Table 4. Description of demographic, dietary intake, and metabolic
differences between age-, race-, and gender-matched patients with
schizophrenia and bipolar disorder with and without metabolic syn-
drome
Variable
With metabolic
syndrome
(n = 62)
Without
metabolic
syndrome
(n = 94)
p-
value
Demographics
Age, years,
mean (SD)
48.7 (9.7) 43.5 (11.1) 0.004
Race, Caucasian/
African
American, %
83/12 79/16 0.92
Gender, male, % 60 60 0.90
Schizophrenia/
bipolar disorder, %
47/53 52/47 0.51
Atypical
antipsychotic
use, %
68 57 0.17
Cumulative
chlorpromazine
equivalents,
mg, mean (SD)
438.7 (439.0) 401.9 (379.1) 0.58
Mood stabilizer, %a 55 55 0.95
Antidepressant, %a 69 49 0.01
Dietary and lifestyle parameters
Current smoker, % 53 41 0.15
Total calories,
kcal/day,
mean (SD)b
1,973.9 (657.6) 1,973.2 (737.5) 0.96
Total activity
score (TAM2),
MET/min,
mean (SD)
2,902 (2,797) 3,738 (3,856) 0.35
Carbohydrates,
kcal/day,
mean (SD)b
245.2 (92.9) 251.0 (101.1) 0.72
SFA, g/day,
mean (SD)b
27.5 (13.5) 26.5 (12.6) 0.63
Dietary fiber,
g/day, mean (SD)b
17.8 (8.9) 18.2 (9.5) 0.83
Total fat, g/day,
mean (SD)b
79.9 (34.8) 77.7 (34.5) 0.69
PUFA, g/day,
mean (SD)b
16.6 (9.1) 16.9 (8.7) 0.85
Vitamin D, lg/day,
mean (SD)b
7.7 (7.7) 7.4 (12.7) 0.87
Glycemic
index (glucose
reference),
mean (SD)
59.7 (4.8) 59.8 (7.1) 0.93
Omega 3 fatty
acids, g/day,
mean (SD)b
1.6 (0.9) 1.8 (1.0) 0.38
Omega 6 fatty
acids, g/day,
mean (SD)b
16.3 (8.9) 16.7 (8.7) 0.80
Omega 6/omega 3
ratio, mean (SD)
11.0 (4.4) 10.4 (4.6) 0.64
PUFA = polyunsaturated fatty acids; SD = standard deviation;
SFA = saturated fatty acids.
aCurrent medication.
bAmount consumed per day.
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non-smoking) and had a lower incidence of AAP
use. Additionally, although the subjects diagnosed
with bipolar disorder had overall a similar percent-
age receiving AAPs (~80%), only half of the sub-
jects with bipolar disorder were using an AAP with
greater weight liability versus approximately three-
fourths of the subjects with schizophrenia. Thus,
the similarities in metabolic syndrome occurrence
between the subjects with schizophrenia and bipo-
lar disorder are troublesome given the fact that
those diagnosed with bipolar disorder appeared to
have overall lower risk factors related to diet, life-
style, and medication. In general, polypharmacy is
very common within the mental health disorder
population, and this can also be seen in our study
subjects, with antipsychotic use being seen in 50–
70% of subjects, mood stabilizer use being seen in
30–70%, and antidepressant use being seen in 50–
60%. While many individual agents have been
associated with the occurrence of weight gain, the
pathophysiology behind these associations varies
depending on the agent being examined, but may
be associated with the pharmacologic eﬀect of
medication on histamine, serotonin, and norepi-
nephrine neurotransmission (43).
Lastly, we examined diﬀerences in dietary and
lifestyle factors based upon metabolic syndrome
criteria and found few diﬀerences. While most of
the metabolic measures associated with metabolic
syndrome (i.e., glucose, lipids, and BMI) were
higher in those meeting NCEP-ATP-III criteria, no
diﬀerences were found in AAP use, total chlor-
promazine equivalents, mood stabilizer use, age,
race, and gender. For dietary intake, no diﬀerences
were found between the metabolic syndrome
groups. Our regression model also mirrored this,
but showed an interesting relationship between
antidepressant use and metabolic syndrome, which
remained signiﬁcant after we controlled for age dif-
ferences. Many antidepressants have been associ-
ated with weight loss and not weight gain, making
this ﬁnding intriguing. The most commonly used
antidepressants in our study group were bupropion
and citalopram, which have diﬀerent pharmaco-
logic proﬁles. In general, bupropion has not been
associated with signiﬁcant weight gain, while cita-
lopram may be associated with some weight gain
with long-term use (44, 45). This then led us to
hypothesize that antidepressant diﬀerences may be
due to diagnostic distribution diﬀerences between
the metabolic syndrome groups; however, no dif-
ferences were found (Table 4). It could be that
residual depressive symptoms and potential vegeta-
tive symptoms may be contributing to metabolic
syndrome occurrence; however, this hypothesis is
still very preliminary as we did not measure psy-
chopathology as part of this study. While aﬀective
symptomatology within bipolar disorder is
undoubtedly key, this has been less studied within
schizophrenia, but is currently gaining interest
(46). It is also important to point out the high per-
centage of patients in general who were receiving
antidepressants as part of our investigation
(~59%), as polypharmacy has also been implicated
as a risk factor for metabolic syndrome (47). Addi-
tionally, long-standing research has shown a rela-
tionship between depression and cardiovascular
disease (48). Thus, our reported relationship
between antidepressant use and metabolic syn-
drome may be a surrogate marker for this known
association. Regardless, for those patients with
mental illness who require antidepressant use,
thorough education regarding cardiovascular dis-
ease as well as metabolic monitoring is necessary
when treatment is started. Although lifestyle and
dietary habits are extremely important in maintain-
ing cardiovascular health, we were unable to ﬁnd
signiﬁcant dietary and/or lifestyle diﬀerences that
predicted metabolic syndrome risk in subjects with
bipolar disorder and schizophrenia.
Only one other study involving greater than
100 individuals has examined the dietary intake
of individuals with schizophrenia (49). As part of
this investigation, intake of antioxidants (vitamins
A, C, and E) and fatty acids was estimated using
a 24-hour diet recall similar to our investigation.
However, in contrast to our study, these authors
reported that subjects with schizophrenia had ele-
vated saturated and polyunsaturated fatty acid
intake, which was signiﬁcant compared to the
NHANES Cycle III results (50), and antioxidant
intake was not signiﬁcantly diﬀerent between
cases and controls. A smaller study examining 88
patients found that the BMI for individuals with
schizophrenia was signiﬁcantly higher than in
controls. In addition, the schizophrenia group
consumed signiﬁcantly less carbohydrates, calo-
ries, total fat, saturated fat, monounsaturated
fatty acids, polyunsaturated fatty acids, ﬁber,
folate, alcohol, and sodium, and signiﬁcantly
more caﬀeine than the NHANES group (51).
Thus, these data seem to agree with our current
analysis.
The sole examination of the dietary intake of
patients with bipolar disorder involved 23 women
and found a signiﬁcantly higher glycemic index
compared to negative controls (52). In addition,
their diet was generally classiﬁed as ‘western’,
reﬂecting consumption of foods such as processed
meats, pizza, chips, hamburgers, white bread,
sugar, ﬂavored milk drinks, and beer. This is very
similar to our data showing an N-6/N-3 ratio
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~10, indicating a more ‘westernized’ diet, in the
bipolar and schizophrenia groups, as well as our
metabolic syndrome groups (53). Most impor-
tantly, 40% of our study subjects met metabolic
syndrome criteria before or during their early
40s, which is younger than reported in the gen-
eral population, but in line with other reports
(1). The bipolar disorder group, despite an over-
all healthier lifestyle, seemed to show a similar
rate of metabolic syndrome compared to subjects
with schizophrenia.
Limitations
While the results of this study are interesting, we
need to be mindful of limitations. Our cross-sec-
tional design does not allow for ‘cause and eﬀect’
relationships. Additionally, we acknowledge that
the persons administering the 24-hour food
recount for our subjects were not the same individ-
uals collecting these data as part of the NHANES
study and that these diﬀerences in study personnel
may introduce an unknown bias. While these limi-
tations may be important to recognize for our
analysis related to the NHANES subjects, for our
secondary analysis between the matched subjects
with bipolar disorder and schizophrenia the same
registered dieticians used the same standardized
procedures to collect the data, and thus these com-
parisons may be the most important to consider.
Use of the NHANES data, while important, may
not represent a timely indication of metabolic syn-
drome incidence within the general population
since these data are from 1999 to 2000 and our
data were collected from 2007 to 2011. Addition-
ally, since we were unable to match subjects based
on socioeconomic status or geographic region, the
limitations associated with these potential diﬀer-
ences also need to be acknowledged. This lack of
matching is interesting because there are data sug-
gesting that poorer dietary intake does correlate
with socioeconomic status (54). Thus, if this were
to hold true for this analysis, then we would expect
an even greater diﬀerence between the patient
groups compared to the NHANES data, as serious
mental illnesses (speciﬁcally schizophrenia) have
been associated with a lower socioeconomic status
by some investigators, but not all (55–57). Argu-
ably, subjects with a serious mental illness may be
considerably diﬀerent than subjects included in the
NHANES database, and we need to recognize that
the subjects with bipolar disorder and schizophre-
nia may be less able to recall dietary information.
However, to overcome this potential limitation, we
utilized three 24-hour food recounts and followed
the same standardized NHANES procedures, car-
ried out by experienced registered dieticians, in an
eﬀort to obtain accurate data related to usual die-
tary intake, without overburdening subjects with
assessments. Lack of dietary blood levels hinders
our ability to relate the body’s handling of these
nutrients in relation to metabolic syndrome.
Lastly, while the sample size was relatively large
for a mental health study, it would be considered
rather small compared to studies within the general
population and the results of this study need to be
replicated.
Summary
In spite of the clear presence of higher rates of
metabolic syndrome in both the bipolar and the
schizophrenia groups, very few dietary diﬀerences
could be discerned between the schizophrenia,
bipolar disorder, and NHANES subject groups.
Within the patient groups stratiﬁed by metabolic
syndrome criteria and assessed by identical proce-
dures, few diﬀerences in dietary and lifestyle prac-
tices could be discerned, suggesting that the lack
of an association between metabolic syndrome
and lifestyle factors is not an artifact of inaccurate
recall of the patients. While these ﬁndings should
not be taken to imply that dietary and lifestyle
factors are not important in the development of
metabolic syndrome in the general population,
they do suggest that the mechanisms behind meta-
bolic complications in individuals with serious
mental illness are more complicated. It may be the
case that the inﬂuence of pharmacologic agents on
the development of these complications overrides
lifestyle factors. If so, further research is war-
ranted to design optimal interventions to combat
these potentially life-threatening medication-
related adverse events. Additional research speciﬁc
to subjects diagnosed with bipolar disorder should
also be undertaken to parse out the speciﬁc risk
factors related to metabolic syndrome develop-
ment, as our data suggest that, despite exhibiting
‘healthier’ lifestyle practices and lower AAP use,
metabolic syndrome occurrence is elevated in
these subjects.
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